

**Clinical Trial Supplies Market by Services (Manufacturing, Sourcing, Packaging, Labelling, Logistics), Phases, Type (Small Molecules, Biologics, Vaccines), Therapeutic Areas (Oncology, Neurology, CVD, Ophthalmology, Dermatology) - Global Forecast to 2030**

Market Report | 2025-03-31 | 415 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global Clinical Trial Supplies market is anticipated to reach USD 8.18 billion in 2030 from USD 5.34 billion in 2025, with a significant CAGR of 8.9%. The clinical trial supplies market is driven by the increasing volume and complexity of global clinical trials, the rise of personalized medicine, and stringent regulatory requirements. Decentralized and adaptive trial designs are fueling demand for specialized supply chain solutions, including direct-to-patient logistics and just-in-time inventory management. Growing biologics and cell & gene therapy trials necessitate temperature-controlled storage and distribution. Digitalization, such as IoT-enabled tracking and AI-driven demand forecasting, is optimizing supply chain efficiency.

"Logistics & Distribution Services dominated the service segment"

Based on services the market is segmented into Logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services. Logistics & Distribution Services dominated the market in 2024 and Sourcing & Procurement Services is anticipated to grow at higher CAGR owing to increasing complexity of trial protocols, the globalization of clinical studies, and the rising demand for cost-effective supply chain management. Sponsors and CROs are outsourcing procurement to specialized vendors to ensure regulatory compliance, mitigate supply risks, and optimize inventory management.

"Phase III segment dominate the phase segment in 2024"

The phase segment is further divided into Phase I, Phase II, Phase III, Phase IV and Phase BA/BE. The rise of biologics, cell & gene therapies, and personalized medicine has further intensified the demand for specialized storage and transportation solutions in Phase III trials. The Phase II segment is anticipated to grow at a significant CAGR during the forecast period in the Clinical Trial

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

Supplies Market owing to the rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments.

"Pharmaceutical & Biotechnology Companies dominated the segment"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and others. Pharmaceutical & biotechnology companies dominated the segment in 2024. With the continuous expansion of R&D pipelines, increased investments in innovative therapies, and the globalization of clinical trials, pharmaceutical and biotechnology companies remain the largest consumers of clinical trial supplies, reinforcing their dominance in the market. Additionally, CROs and CDMOs are expanding their capabilities by integrating digital technologies such as AI-driven supply chain optimization, blockchain for traceability, and real-time inventory management to enhance efficiency and compliance.

"North America: the largest share of the Clinical Trial Supplies market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the Clinical Trial Supplies market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The growing adoption of decentralized trials, advanced cold chain logistics, and direct-to-patient (DTP) delivery models has further strengthened the U.S. market. Moreover, the presence of a well-established clinical trial infrastructure, advanced healthcare system, and strong government funding for drug development has contributed to the country's leading position. The increasing demand for biologics, biosimilars, and advanced therapies is driving the need for specialized supply chain services, cold chain logistics, and regulatory-compliant distribution networks. With continuous improvements in healthcare infrastructure, favorable government policies, and growing outsourcing trends, APAC is expected to experience robust growth in the clinical trial supplies market in the coming years.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the Clinical Trial Supplies market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

The prominent players operating in the Clinical Trial Supplies market are Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany), Aenova Holding GmbH (Germany), Klifo (Denmark), IPS Pharma (UK), Corex Logistic Limited (Ireland), Biocair (US), Piramal Group (India), Lonza (Switzerland), OCT Group LLC (Germany), Ancillare LP (US), N-SIDE (Belgium), Adallen Pharma (UK), Uniphar Group (Ireland), Clinical Services International (UK) and among others.

Research Coverage:

Clinical Trial Supplies market report is segmented based on services (Logistics & Distribution, Storage & Retention, Packaging, Labeling and Blinding{Primary Packaging, Secondary Packaging and Labeling & Binding}, Manufacturing, Comparator Sourcing , and Other Services), Phase ( Phase I, Phase II, Phase III, Phase IV and Phase BA/BE), Type (Small Molecules, Biologics [Monoclonal Antibodies, Vaccines and Others], Medical Devices), Therapeutic Area (Oncology, Neurology, Respiratory Disorder, Metabolic Disorder/Endocrinology, Cardiovascular System Disorders, Dermatology, Gastrointestinal, Immunological Disorder, Infectious Diseases, Psychiatry, Ophthalmology, Haematology, Genitourinary and Women's Health, and Others), End Users (pharmaceutical & biotechnology companies, CROs & CDMOs and others). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Clinical Trial Supplies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Clinical Trial Supplies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

the Clinical Trial Supplies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers ( Increasing Number of Clinical Trials, Technological Advancements in Supply Chain Management), restraints (High Cost of clinical trial supplies), opportunities (Rise of Decentralized & Direct-to-Patient (DTP) Trials) and Challenges ( managing global supply chains) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on upcoming technologies in Clinical Trial Supplies, research and development activities, and new service launches in the Clinical Trial Supplies market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Clinical Trial Supplies market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Imac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany) and among others

## **Table of Contents:**

1	INTRODUCTION	38
1.1	STUDY OBJECTIVES	38
1.2	MARKET DEFINITION	38
1.3	MARKET SCOPE	39
1.3.1	MARKETS & REGIONS COVERED	39
1.3.2	INCLUSIONS & EXCLUSIONS	40
1.3.3	YEARS CONSIDERED	40
1.3.4	CURRENCY CONSIDERED	41
1.4	STAKEHOLDERS	41
1.5	SUMMARY OF CHANGES	41
2	RESEARCH METHODOLOGY	43
2.1	RESEARCH DATA	43
2.1.1	SECONDARY DATA	44
2.1.2	PRIMARY RESEARCH	45
2.2	MARKET SIZE ESTIMATION	46
2.2.1	GLOBAL MARKET ESTIMATION	46
2.2.1.1	Insights from primary experts	48
2.2.2	SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)	49
2.3	MARKET GROWTH RATE PROJECTIONS	50
2.4	DATA TRIANGULATION	52
2.5	RESEARCH ASSUMPTIONS	53
2.6	RESEARCH LIMITATIONS	54
2.7	RISK ANALYSIS	54
3	EXECUTIVE SUMMARY	55
4	PREMIUM INSIGHTS	60
4.1	CLINICAL TRIAL SUPPLIES MARKET OVERVIEW	60
4.2	NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2024)	61

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

4.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2025 VS. 2030	61
4.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	62
5 MARKET OVERVIEW	63
5.1 INTRODUCTION	63
5.2 MARKET DYNAMICS	64
5.2.1 DRIVERS	65
5.2.1.1 Growth in clinical trials & drug development	65
5.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies	66
5.2.1.3 Rising demand for personalized medicine and biologics	66
5.2.2 RESTRAINTS	67
5.2.2.1 High costs associated with clinical trial supplies	67
5.2.3 OPPORTUNITIES	67
5.2.3.1 Rise in decentralized and virtual trials	67
5.2.3.2 Integration of digital technologies in supply chain management	68
5.2.4 CHALLENGES	68
5.2.4.1 Supply chain disruptions and drug shortages	68
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69
5.4 VALUE CHAIN ANALYSIS	69
5.5 ECOSYSTEM ANALYSIS	72
5.5.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS	73
5.5.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS	73
5.5.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS	74
5.5.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES	74
5.6 PRICING ANALYSIS	75
5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE)	75
5.6.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE)	76
5.7 INVESTMENT AND FUNDING SCENARIO	77
5.8 TECHNOLOGY ANALYSIS	77
5.8.1 KEY TECHNOLOGIES	77
5.8.1.1 Serialization & track-and-trace technologies	77
5.8.1.2 Interactive response technology (IRT/IVR/IWR)	78
5.8.1.3 Cold chain & temperature monitoring solutions	78
5.8.2 COMPLEMENTARY TECHNOLOGIES	78
5.8.2.1 Artificial intelligence (AI) & machine learning (ML)	78
5.8.2.2 Blockchain for supply chain transparency	78
5.8.3 ADJACENT TECHNOLOGIES	78
5.8.3.1 Cryopreservation & advanced storage technologies	78
5.8.3.2 Advanced robotics in warehousing & distribution	79
5.9 KEY CONFERENCES AND EVENTS, 2025-2026	79
5.10 REGULATORY LANDSCAPE	80
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	80
5.10.2 REGULATORY FRAMEWORK	83
5.10.2.1 North America	83
5.10.2.1.1 US	83
5.10.2.1.2 Canada	84
5.10.2.2 Europe	84
5.10.2.2.1 Germany	84

5.10.2.2.2 France	84
5.10.2.2.3 Italy	84
5.10.2.3 Asia Pacific	84
5.10.2.3.1 Japan	84
5.10.2.3.2 China	84
5.10.2.3.3 India	84
5.10.2.4 Latin America	85
5.10.2.4.1 Brazil	85
5.10.2.5 Middle East & Africa	85
5.10.2.5.1 GCC Countries	85
5.10.2.5.2 South Africa	85
5.11 PORTER'S FIVE FORCES ANALYSIS	85
5.11.1 THREAT OF NEW ENTRANTS	86
5.11.2 BARGAINING POWER OF SUPPLIERS	86
5.11.3 BARGAINING POWER OF BUYERS	87
5.11.4 THREAT OF SUBSTITUTES	87
5.11.5 INTENSITY OF COMPETITIVE RIVALRY	87
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA	87
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS	88
5.12.2 BUYING CRITERIA	89
5.13 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET	90
5.13.1 INTRODUCTION	90
5.13.2 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM	92
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE	93
6.1 INTRODUCTION	94
6.2 LOGISTICS & DISTRIBUTION SERVICES	94
6.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH	94
6.3 COMPARATOR SOURCING SERVICES	98
6.3.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET	98
6.4 PACKAGING, LABELING, AND BLINDING SERVICES	101
6.4.1 PRIMARY PACKAGING SERVICES	105
6.4.1.1 Increasing demand for innovative drug formulations to support market growth	105
6.4.2 SECONDARY PACKAGING SERVICES	108
6.4.2.1 Increasing complexity of global clinical trials to propel market	108
6.4.3 LABELING & BLINDING SERVICES	111
6.4.3.1 Rising number of randomized and double-blind studies to propel market	111
?	
6.5 MANUFACTURING SERVICES	114
6.5.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH	114
6.6 STORAGE & RETENTION SERVICES	117
6.6.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH	117
6.7 OTHER SERVICES	121
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE	125
7.1 INTRODUCTION	126
7.2 PHASE III	126
7.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH	126
7.3 PHASE II	130

7.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH	130
7.4 PHASE I	133
7.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH	133
7.5 PHASE IV	137
7.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH	137
7.6 PHASE BA/BE	140
7.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH	140
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE	144
8.1 INTRODUCTION	145
8.2 SMALL MOLECULES	145
8.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS	145
8.3 BIOLOGICS	149
8.3.1 MONOCLONAL ANTIBODIES	153
8.3.1.1 Rising demand for monoclonal antibodies to drive growth	153
8.3.2 VACCINES	156
8.3.2.1 Increased focus on development of novel vaccines to drive growth	156
8.3.3 OTHER BIOLOGICS	160
8.4 MEDICAL DEVICES	163
8.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH	163
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA	167
9.1 INTRODUCTION	168
9.2 ONCOLOGY	169
9.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH	169
9.3 NEUROLOGY	173
9.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH	173
9.4 RESPIRATORY DISORDERS	177
9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH	177
9.5 METABOLIC DISORDERS/ENDOCRINOLOGY	180
9.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH	180
9.6 CARDIOVASCULAR SYSTEM DISORDERS	184
9.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH	184
9.7 DERMATOLOGY	187
9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH	187
9.8 GASTROINTESTINAL SYSTEM DISORDERS	191
9.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND	191
9.9 IMMUNOLOGICAL DISORDERS	194
9.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH	194
9.10 INFECTIOUS DISEASES	198
9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH	198
9.11 PSYCHIATRY	202
9.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH	202
9.12 OPHTHALMOLOGY	205
9.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH	205
9.13 HEMATOLOGY	209
9.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH	209
9.14 GENITOURINARY & WOMEN'S HEALTH	212

9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH	212
9.15 OTHER THERAPEUTIC AREAS	216
10 CLINICAL TRIAL SUPPLIES MARKET, BY REGION	220
10.1 INTRODUCTION	221
10.2 NORTH AMERICA	221
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA	222
10.2.2 US	227
10.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth	227
10.2.3 CANADA	230
10.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth	230
?	
10.3 EUROPE	234
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE	234
10.3.2 GERMANY	239
10.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market	239
10.3.3 UK	243
10.3.3.1 Expanding tax credits leading to encourage growth	243
10.3.4 FRANCE	246
10.3.4.1 Evolving regulatory landscape to stimulate growth	246
10.3.5 ITALY	250
10.3.5.1 Increasing number of drug approvals to accelerate growth	250
10.3.6 SPAIN	253
10.3.6.1 Favorable clinical trial network in public health system to sustain growth	253
10.3.7 SWITZERLAND	256
10.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market	256
10.3.8 NETHERLANDS	260
10.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth	260
10.3.9 REST OF EUROPE	263
10.4 ASIA PACIFIC	267
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	267
10.4.2 CHINA	273
10.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth	273
10.4.3 JAPAN	277
10.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth	277
10.4.4 INDIA	280
10.4.4.1 Rise in early-phase clinical trials to spur growth	280
10.4.5 AUSTRALIA	284
10.4.5.1 Increasing research funding to favor growth	284
10.4.6 SOUTH KOREA	287
10.4.6.1 Growing focus on new drug development research to drive market	287
10.4.7 SINGAPORE	291
10.4.7.1 Advanced research facilities to intensify growth	291
10.4.8 REST OF ASIA PACIFIC	294
10.5 LATIN AMERICA	298
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA	298
10.5.2 BRAZIL	302
10.5.2.1 Regulatory improvements to support growth	302

10.5.3 MEXICO	306
10.5.3.1 Expanding landscape of clinical trials to boost market	306
10.5.4 REST OF LATIN AMERICA	309
10.6 MIDDLE EAST	312
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST	312
10.6.2 GCC COUNTRIES	317
10.6.2.1 Saudi Arabia	320
10.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth	320
10.6.2.2 UAE	324
10.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth	324
10.6.2.3 Rest of GCC Countries	327
10.6.3 REST OF MIDDLE EAST	330
10.7 AFRICA	333
10.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH	333
10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA	334
11 COMPETITIVE LANDSCAPE	338
11.1 INTRODUCTION	338
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN	338
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET	338
11.3 REVENUE ANALYSIS, 2020-2024	340
11.4 MARKET SHARE ANALYSIS, 2024	341
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	343
11.5.1 STARS	343
11.5.2 EMERGING LEADERS	343
11.5.3 PERVERSIVE PLAYERS	343
11.5.4 PARTICIPANTS	343
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024	345
11.5.5.1 Company footprint	345
11.5.5.2 Region footprint	346
11.5.5.3 Service footprint	347
11.5.5.4 Type footprint	348
11.5.5.5 End-user footprint	349
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	349
11.6.1 PROGRESSIVE COMPANIES	349
11.6.2 RESPONSIVE COMPANIES	349
11.6.3 DYNAMIC COMPANIES	350
11.6.4 STARTING BLOCKS	350
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	351
11.6.5.1 Detailed list of key startups/SMEs	351
11.6.5.2 Competitive benchmarking of key startups/SMEs	352
?	
11.7 COMPANY VALUATION & FINANCIAL METRICS	353
11.7.1 COMPANY VALUATION	353
11.7.2 FINANCIAL METRICS	353
11.8 BRAND/SERVICE COMPARISON	354
11.9 COMPETITIVE SCENARIO	355
11.9.1 DEALS	355

11.9.2 EXPANSIONS	356
12 COMPANY PROFILES	357
12.1 KEY PLAYERS	357
12.1.1 THERMO FISHER SCIENTIFIC INC.	357
12.1.1.1 Business overview	357
12.1.1.2 Services offered	358
12.1.1.3 Recent developments	359
12.1.1.3.1 Service launches	359
12.1.1.3.2 Deals	359
12.1.1.3.3 Expansions	360
12.1.1.4 MnM view	360
12.1.1.4.1 Right to win	360
12.1.1.4.2 Strategic choices	360
12.1.1.4.3 Weaknesses & competitive threats	360
12.1.2 NOVO HOLDINGS A/S	361
12.1.2.1 Business overview	361
12.1.2.2 Services offered	362
12.1.2.3 Recent developments	363
12.1.2.3.1 Deals	363
12.1.2.3.2 Expansions	364
12.1.2.4 MnM view	364
12.1.2.4.1 Right to win	364
12.1.2.4.2 Strategic choices	364
12.1.2.4.3 Weaknesses & competitive threats	365
12.1.3 UNITED PARCEL SERVICE OF AMERICA, INC.	366
12.1.3.1 Business overview	366
12.1.3.2 Services offered	366
12.1.3.3 MnM view	367
12.1.3.3.1 Right to win	367
12.1.3.3.2 Strategic choices	367
12.1.3.3.3 Weaknesses & competitive threats	368
?	
12.1.4 EUROFINS SCIENTIFIC	369
12.1.4.1 Business overview	369
12.1.4.2 Services offered	370
12.1.4.3 MnM view	371
12.1.4.3.1 Right to win	371
12.1.4.3.2 Strategic choices	371
12.1.4.3.3 Weaknesses & competitive threats	371
12.1.5 PIRAMAL PHARMA LIMITED	372
12.1.5.1 Business overview	372
12.1.5.2 Services offered	373
12.1.5.3 MnM view	374
12.1.5.3.1 Right to win	374
12.1.5.3.2 Strategic choices	374
12.1.5.3.3 Weaknesses & competitive threats	374
12.1.6 IQVIA	375

12.1.6.1 Business overview	375
12.1.6.2 Services offered	377
12.1.7 ICON PLC	378
12.1.7.1 Business overview	378
12.1.7.2 Services offered	379
12.1.7.3 Recent developments	380
12.1.7.3.1 Deals	380
12.1.8 LONZA	381
12.1.8.1 Business overview	381
12.1.8.2 Services offered	382
12.1.8.3 Recent developments	382
12.1.8.3.1 Deals	382
12.1.9 UNIPHAR GROUP PLC	383
12.1.9.1 Business overview	383
12.1.9.2 Services offered	384
12.1.10 ALMAC GROUP	385
12.1.10.1 Business overview	385
12.1.10.2 Services offered	385
12.1.10.3 Recent developments	386
12.1.10.3.1 Expansions	386
12.1.11 SHARP SERVICES, LLC	387
12.1.11.1 Business overview	387
12.1.11.2 Services offered	387
12.1.12 PCI PHARMA SERVICES	389
12.1.12.1 Business overview	389
12.1.12.2 Services offered	389
12.1.12.3 Recent developments	390
12.1.12.3.1 Expansions	390
12.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION	391
12.1.13.1 Business overview	391
12.1.13.2 Services offered	391
12.1.13.3 Recent developments	392
12.1.13.3.1 Deals	392
12.1.14 BIOCAIR	393
12.1.14.1 Business overview	393
12.1.14.2 Services offered	393
12.2 OTHER PLAYERS	394
12.2.1 CENCORA, INC.	394
12.2.2 CLINIGEN LIMITED	395
12.2.3 KLIFO	396
12.2.4 IPS PHARMA	397
12.2.5 COREX LOGISTICS LIMITED	398
12.2.6 OCT GROUP LLC	399
12.2.7 MYONEX	400
12.2.8 INCEPTUA GROUP	401
12.2.9 ANCILLARE, LP	402
12.2.10 ADALLEN PHARMA	403

12.2.11 CLINICAL SERVICES INTERNATIONAL (CSI)	404
12.2.12 NUVISAN GMBH	405
12.2.13 AENOVA HOLDING GMBH	406
13 APPENDIX	407
13.1 DISCUSSION GUIDE	407
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	411
13.3 CUSTOMIZATION OPTIONS	413
13.4 RELATED REPORTS	413
13.5 AUTHOR DETAILS	414

**Clinical Trial Supplies Market by Services (Manufacturing, Sourcing, Packaging, Labelling, Logistics), Phases, Type (Small Molecules, Biologics, Vaccines), Therapeutic Areas (Oncology, Neurology, CVD, Ophthalmology, Dermatology) - Global Forecast to 2030**

Market Report | 2025-03-31 | 415 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

Zip Code\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)